

## [Neostigmine](#)

Essential medicine status

Section:

[20. Muscle relaxants \(peripherally-acting\) and cholinesterase inhibitors](#)

ATC codes: [N07AA01](#)

EMLc

Indication

Myasthenia gravis ICD11 code: [8C70.Z](#)

INN

Neostigmine bromide

Medicine type

Chemical agent

List type

Core

Formulations

**Parenteral > General injections > unspecified:** 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate) ; 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)

**Oral > Solid > tablet:** 15 mg (neostigmine bromide) (EML)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1989 ([TRS 796](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 950](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Neostigmine](#)

DrugBank

[Neostigmine](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the deletion of neostigmine 15 mg tablets from the EMLc